Covid booster needed for protection against Omicron variants, studies show

A COVID-19 booster dose will provide strong and broad antibody protection against Omicron sublineage variants of the SARS-CoV-2 virus, two new studies using serum from human blood samples suggest.

vaccine
Representational Image
Press Trust of India Washington
4 min read Last Updated : May 20 2022 | 5:13 PM IST

A COVID-19 booster dose will provide strong and broad antibody protection against Omicron sublineage variants of the SARS-CoV-2 virus, two new studies using serum from human blood samples suggest.

Researchers from the Ohio State University in the US tested neutralising antibody levels against the BA.2 and BA.3 Omicron variants and Deltacron, a recombinant variant created by the exchange of genetic material between Delta and Omicron.

The studies, published in the New England Journal of Medicine (NEJM), and Cell Host & Microbe journal, showed that a third mRNA vaccine dose was required to generate a high enough concentration of antibodies to neutralise BA.2 and Deltacron, as well as other Omicron variants, including the original BA.1, and BA.1.1.

Antibodies produced by just the two-dose series of mRNA vaccines were enough to neutralise BA.3 -- a sign this variant is not likely to produce a new surge of Omicron infections, the researchers said.

"Three doses is better for everything," said Shan-Lu Liu, the senior author of both studies and a virology professor at Ohio State University.

"People have been asking about the recombinant Deltacron and also BA.3, and now we have an answer. And it's good news," said Liu

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: May 20 2022 | 5:12 PM IST

Next Story